(Q40571747)

English

The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization

scientific article published on November 2002

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 September 2017

The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization (English)

1 reference

Europe PubMed Central

21 September 2017

0 references

Hantaan River virus

1 reference

based on heuristic

inferred from title

passive immunization

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

5

object named as

Shibo Jiang

1 reference

Europe PubMed Central

21 September 2017

author name string

Zhikai Xu

1

1 reference

Europe PubMed Central

21 September 2017

Lixin Wei

2

1 reference

Europe PubMed Central

21 September 2017

Liya Wang

3

1 reference

Europe PubMed Central

21 September 2017

Haitao Wang

4

1 reference

Europe PubMed Central

21 September 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 November 2002

1 reference

Europe PubMed Central

21 September 2017

Biochemical and Biophysical Research Communications

1 reference

Europe PubMed Central

21 September 2017

298

1 reference

Europe PubMed Central

21 September 2017

4

1 reference

Europe PubMed Central

21 September 2017

552-558

1 reference

Europe PubMed Central

21 September 2017

Hantaviruses: A Global Disease Problem

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Hantaviruses: clinical, microbiologic, and epidemiologic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Hantavirus infections.

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Hantavirus Pulmonary Syndrome in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Hantavirus pulmonary syndrome: a clinical description of 17 patients with a newly recognized disease. The Hantavirus Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Hantaviruses: genome structure, expression and evolution

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Direct genetic detection of Dobrava virus in Greek and Albanian patients with hemorrhagic fever with renal syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Emerging viral diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Passive antibody therapies: progress and continuing challenges

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Ganciclovir and hyperimmunoglobulin for treating cytomegalovirus infection in bone marrow transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Human Monoclonal Antibodies Neutralizing Cytomegalovirus (CMV) for Prophylaxis of CMV Disease: Report of a Phase I Trial in Bone Marrow Transplant Recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Prevention and treatment of respiratory syncytial virus and parainfluenza viruses in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Characterization of Hantaan virus envelope glycoprotein antigenic determinants defined by monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Protective role of antigenic sites on the envelope protein of Hantaan virus defined by monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Characteristics of passive immunity against hantavirus infection in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

The antigenic analysis of haemorrhagic fever with renal syndrome viruses in China by monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Hemagglutination-Inhibiting Antibody in Hemorrhagic Fever with Renal Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Spectrum of hantavirus infection: hemorrhagic fever with renal syndrome and hantavirus pulmonary syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Hantaviruses are likely threat to NATO forces in Bosnia and Herzegovina and Croatia

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Pathogenesis of puumala and other hantavirus infections

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Prospective, Double-Blind, Concurrent, Placebo-Controlled Clinical Trial of Intravenous Ribavirin Therapy of Hemorrhagic Fever with Renal Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Primary humoral immune responses to formalin inactivated hemorrhagic fever with renal syndrome vaccine (Hantavax): consideration of active immunization in South Korea

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Clinical evaluation of a vaccinia-vectored Hantaan virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Bacterial expression of neutralizing mouse monoclonal antibody Fab fragments to Hantaan virus

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Expression of a human, neutralizing monoclonal antibody specific to puumala virus G2-protein in stably-transformed insect cells

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Human memory cytotoxic T-lymphocyte (CTL) responses to Hantaan virus infection: identification of virus-specific and cross-reactive CD8(+) CTL epitopes on nucleocapsid protein

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

Ebola virus can be effectively neutralized by antibody produced in natural human infection

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2802%2902491-9

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0006-291X(02)02491-9

1 reference

Europe PubMed Central

21 September 2017

1 reference

Europe PubMed Central

21 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40571747&oldid=2099986951"